Phase 2 study for people with Bladder Cancer

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting

Phase Phase 2

Sponsor AstraZeneca

Registry number NCT06960577

Started 15 May 2025 Today 16 October 2026 Estimated completion 30 August 2028

Where this trial is running

Trial sites and the status recorded for each
Site	City	State or country	Status at this site
Research Site	Chermside	QLD	Recruiting
Research Site	Elizabeth Vale	SA	Recruiting
Research Site	Heidelberg	VIC	Recruiting
Research Site	Hong Kong	Australia	Recruiting
Research Site	Kogarah	NSW	Recruiting
Research Site	Macquarie University	NSW	Recruiting
Research Site	Murdoch	WA	Recruiting
Research Site	Port Macquarie	NSW	Withdrawn
Research Site	St Leonards	NSW	Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over

Sex Anyone, regardless of sex

Healthy volunteers Not accepted

Enrolment target 150

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional or mixed transitional cell histology

* Participants must be planning to undergo radical cystectomy

* Participants who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer

* ECOG performance status of 0 or 1

* Minimum life expectancy of 12 weeks at first dose of study medication

Exclusion criteria:

* Evidence of lymph node (N2-N3) or metastatic (M1) disease

* Inoperable tumour(s) with fixation to the pelvic wall on clinical examination

* Prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD 1, anti-PD L1 and anti-PD-L2 antibodies, excluding Bacillus Calmette-Guérin

* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab

* Any concomitant medication known to be contraindicated with ddMVAC.

* Uncontrolled intercurrent illness.

Dates on the record

Started 15 May 2025

Estimated completion 30 August 2028

Registry last updated 8 October 2026

Checked by Voxsanity 15 October 2026

Results, publications and the official record

No results are posted on the official record yet.
No publications are listed on the official record yet.
Official record and contacts on ClinicalTrials.gov – contact details for each site are kept there, and are not copied onto this page.

Sources and dates

ClinicalTrials.gov – the record this page reformats
ClinicalTrials.gov processing date: 8 October 2026.
This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.

Voxsanity

Clinical trials recruiting in Australia, from the public registries · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial, which may be relevant to my care:

Trial: NCT06960577

Sponsor: AstraZeneca

Phase: Phase 2

Status: Recruiting

Condition: Bladder Cancer

More information: https://clinicaltrials.gov/study/NCT06960577

Eligibility criteria, as the registry published them

Reproduced exactly, unedited. Written for researchers rather than for patients.

Inclusion Criteria:

Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional or mixed transitional cell histology
Participants must be planning to undergo radical cystectomy
Participants who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer
ECOG performance status of 0 or 1
Minimum life expectancy of 12 weeks at first dose of study medication

Exclusion criteria:

Evidence of lymph node (N2-N3) or metastatic (M1) disease
Inoperable tumour(s) with fixation to the pelvic wall on clinical examination
Prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD 1, anti-PD L1 and anti-PD-L2 antibodies, excluding Bacillus Calmette-Guérin
Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab
Any concomitant medication known to be contraindicated with ddMVAC.
Uncontrolled intercurrent illness.

A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a registered health practitioner to access unapproved therapeutic goods for individual patients.

Not medical advice. Voxsanity reformats information published by public registries. It does not give medical advice and is not a substitute for talking to your doctor.